Please assess the completion status of the following clinical trial:

Trial Title: A Dose-escalating Study to Evaluate the Immunogenicity and Safety of Rotavin-M1 Vaccine in Healthy Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* At dose 1~  1. A healthy male or female, 6 to 12 weeks of age (42 days to 84 days of age).~ 2. Full term gestation (\>=37 weeks).~ 3. Birth weight of the subject should be \>=2.5 kg.~ 4. Healthy subjects as established by medical history and clinical examination before entering into the study.~ 5. Did not use any dose of Rota virus vaccine.~ 6. Written informed consent obtained from the parent or guardian of the subject.~* At dose 2~  1. Received dose 1.~ 2. Oral informed consent obtained from the parent or guardian of the subject for continuing participate the study.~* At dose 3~  1. Received both dose 1 and dose 2.~ 2. Oral informed consent obtained from the parent or guardian of the subject for continuing participate the study.~Exclusion Criteria:~* At dose 1~  1. Has a chronic disease (cardiovascular, liver, kidney disease).~ 2. Acute disease at the time of enrolment.~ 3. Administering corticosteroids (\> 1mg/kg/day).~ 4. Received any immunosuppressive therapy within 4 week before vaccination (Administration of immunoglobulins and/or any blood product or corticosteroids for \>2 weeks).~ 5. Immunosuppressive or immunodeficient condition.~ 6. Family has immunosuppressive or immunodeficient condition medical history.~ 7. History of high fever convulsion.~ 8. Allergic or reaction with any component of vaccine, includes anaphylactic shock with any antibiotic.~ 9. Preterm of gestation delivery (gestation period \< 37 weeks).~ 10. Low birth weight (\<2.5 kg).~ 11. Fever (axillary temperature \>38oC) within 3 days before or on the day of vaccination.~ 12. Malnutrition.~ 13. Has any type of blood disorder, leukemia, or malignant tumor which can affect the bone marrow or lymph system.~ 14. Use of any investigational or non-registered product (unlicensed drug or vaccine) other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* At dose 2~  1. Acute disease at the time of 2nd dose.~ 2. Administering corticosteroids (\> 1mg/kg/day).~ 3. Received any immunosuppressive therapy within 4 week before vaccination (Administration of immunoglobulins and/or any blood product or corticosteroids for \>2 weeks).~ 4. History of allergic disease or reactions likely to be exacerbated by any component of the study vaccine.~ 5. Fever (axillary temperature \>38oC) within 3 days before or on the day of vaccination.~ 6. Has any type of blood disorder, leukemia, or malignant tumor which can affect the bone marrow or lymph system.~ 7. Use of any investigational or non-registered product (unlicensed drug or vaccine) other than the study vaccine during the study period.~* At dose 3~  1. Acute disease at the time of 3rd dose.~ 2. Administering corticosteroids (\> 1mg/kg/day).~ 3. Received any immunosuppressive therapy within 4 week before vaccination (Administration of immunoglobulins and/or any blood product or corticosteroids for \>2 weeks).~ 4. History of allergic disease or reactions likely to be exacerbated by any component of the study vaccine.~ 5. Fever (axillary temperature \>38oC) within 3 days before or on the day of vaccination.~ 6. Has any type of blood disorder, leukemia, or malignant tumor which can affect the bone marrow or lymph system.~ 7. Use of any investigational or non-registered product (unlicensed drug or vaccine) other than the study vaccine during the study period.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: t

Study Arms:
- Rotavin2H (Type: EXPERIMENTAL): 2 doses of Rotavin-M1 vaccine, 106.3FFU/dose, 2-month separation between doses
- Rotavin2L (Type: EXPERIMENTAL): 2 doses of Rotavin-M1 vaccine, 106.0FFU/dose, 2-month interval between doses
- Rotavin3H (Type: EXPERIMENTAL): 3 doses of Rotavin-M1 vaccine, 106.3FFU/dose, 1-month interval between doses
- Rotavin3L (Type: EXPERIMENTAL): 3 doses of Rotavin-M1, 106.0FFU/dose, 1-month interval between doses

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete